Retatrutide is a once-weekly weight loss injection that combines the actions of three key metabolic hormones: GLP-1 (helps you feel full and keeps blood sugar in balance) GIP (supports insulin release and helps your body process food for energy) Glucagon (tells your body to burn fat for energy) This triple G mechanism sets it apart from Wegovy, which targets one hormone, and Mounjaro, which targets two
According to the Judicial Panel on Multidistrict Litigation (JPML), 2,676 cases are now consolidated, compared to 2,190 in August
Emphasis on Indication [Dulaglutide (Trulicity), Exenatide (Bydureon, Byetta), Liraglutide (Victoza, Saxenda), Semaglutide (Ozempic, Wegovy, Rybelsus), Tirzepatide (Mounjaro, Zepbound)]
The progression from single-agonist (semaglutide) to dual-agonist (tirzepatide) to triple-agonist (retatrutide) tells a clear story about where obesity treatment is heading
This leads to reduced calorie intake and supports sustainable weight loss